. Author manuscript; available in PMC: 2017 Aug 15.

Published in final edited form as: J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):572–578. doi: 10.1097/QAI.0000000000001018

Table 4.

Tuberculosis Risk Using 3 Month HAART Cut-off-Marginal Structural Model

Characteristic	Intention to Treat Analysis		As Treated Analysis

	aOR^a	95% CI	aOR^a	95% CI

HAART status
Not on HAART	Reference	Reference	Reference	Reference
≤3 months of HAART	0.40	0.15, 1.07	0.60	0.25, 1.46
>3 months of HAART	0.39	0.22, 0.69	0.27	0.15, 0.50

aOR, adjusted odds ratio; CI, confidence interval; HAART, highly active antiretroviral therapy; HIV, human immunodeficiency virus; mL, milliliters; US, United States

Adjusted for baseline age, sex, race, Non-US or Canadian born, injection drug use as HIV transmission factor, baseline CD4+ count, baseline HIV-1 viral load, time since study entry (months), and year of enrollment.